Table 2. Strategies for improving specific immunotherapy.
Strategies | Examples | References | |
---|---|---|---|
Molecule-based | |||
Natural molecules | Chemical treatment of extracts | Depigmented aldehyde-treated extracts (house dust mite, grass and tree pollen) |
[17–24] |
Synthetic molecules | Peptides | T-cell peptides of Fel d 1 | [15▪] |
Recombinant molecules | Folding variants | Pru p 3 folding variant | [27] |
Mutants | Mus m 1 structural mutant | [28] | |
Fragments/oligomers | Art v 1 mutation of disulfide bonds | [29] | |
Hybrids | Trimer of Bet v 1 fragment | [30] | |
Fel d 1 with duplicated T-cell epitopes and disrupting of disulfide bonds |
[31] | ||
Feld 1 random mutations | [34] | ||
Der p 1–2 hybrid | [33] | ||
Peptide-carrier fusion proteins | Ole e 1 peptides coupled to KLH | [39] | |
Der p 2 peptides coupled to KLH | [40] | ||
Alt a 1 peptides coupled to KLH | [41] | ||
Phl p 1 peptides fused to VP1 | [43] | ||
Fel d 1 peptides fused to PreS | [44▪] | ||
DNA vaccines | Der p 2 mutant | [47] | |
Der p 1 mature | [48] | ||
Cyn d 1 | [49] | ||
RNA vaccines | [50] | ||
Routes | |||
Oral | Desensitization in food allergy | Peanut flour | [52] |
Edible seeds | Rice seeds with shuffled Cry j 2,Der p 1 fragment, Der f 2 with disrupted disulfide bonds [57] |
[54–56] | |
Sublingual | Recombinant allergens | Natural-like recDer p 2 | [58] |
Epicutaneaous | Pollen extract patches | Grass pollen extract | [60] |
Food allergens | Peanut extract | [61] | |
Intralymphatic | MAT | MAT-Fel d 1 | [62▪] |
Immunomodulation | |||
Conjugated molecules | CpGs | Cry j 1-CpG | [64] |
Vitamin D3 | Fel d 1 Vit D3 | [66] |
KLH, keyhole limpet hemocyanin; MAT, modular antigen transporter.